Drug Design, Development and Therapy (Mar 2014)

Daclatasvir: potential role in hepatitis C [Corrigendum]

  • Lee C

Journal volume & issue
Vol. 2014, no. default
pp. 325 – 326

Abstract

Read online

Lee C. Drug Des Devel Ther. 2013;7:1223–1233. On page 1231 in the "Conclusion" section, line 3 contains incorrect information. The correct sentence is "This review summarizes key preclinical and clinical data of an HCV NS5A inhibitor, DCV, describing its discovery, mechanism of action, resistance profile, in vitro and in vivo efficacy and toxicity, and polymorphism."Read the original article